Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Up 3.4%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s stock price traded up 3.4% during mid-day trading on Friday . The stock traded as high as $18.25 and last traded at $18.25. 358 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 8,025 shares. The stock had previously closed at $17.65.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Trading Up 5.9 %

The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The company has a fifty day simple moving average of $21.08 and a 200-day simple moving average of $20.61. The company has a market capitalization of $557.07 million, a PE ratio of -11.40 and a beta of 1.50.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. The business had revenue of $42.45 million for the quarter, compared to analyst estimates of $36.24 million. During the same quarter in the prior year, the company posted ($0.01) EPS. Analysts predict that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

Large investors have recently modified their holdings of the business. Optiver Holding B.V. acquired a new position in shares of Calliditas Therapeutics AB (publ) in the 4th quarter valued at $25,000. Tower Research Capital LLC TRC lifted its stake in shares of Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after purchasing an additional 3,112 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Calliditas Therapeutics AB (publ) in the 1st quarter valued at $221,000. Finally, Deutsche Bank AG lifted its stake in shares of Calliditas Therapeutics AB (publ) by 26.5% in the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock valued at $2,170,000 after purchasing an additional 18,978 shares during the last quarter. Institutional investors and hedge funds own 2.83% of the company’s stock.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.